UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Clinical cancer research, 2020-03, Vol.26 (6), p.1220-1228

2020

Volltextzugriff (PDF)

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Journal of clinical oncology, 2017-12, Vol.35 (36), p.4035-4041

2017

Volltextzugriff (PDF)

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-05, Vol.372 (21), p.2018-2028

2015

Volltextzugriff (PDF)

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

The lancet oncology, 2019-03, Vol.20 (3), p.383-393

2019

Volltextzugriff (PDF)

Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC

Annals of oncology, 2017-10, Vol.28 Suppl 9, p.ix73

2017

Volltextzugriff (PDF)

Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial

International journal of gynecological cancer, 2016-11, Vol.26 (9), p.1580-1585

2016

Volltextzugriff (PDF)

Coordinate control of axon defasciculation and myelination by laminin-2 and -8

The Journal of cell biology, 2005-02, Vol.168 (4), p.655-666

2005

Volltextzugriff (PDF)

Erbin Regulates Mitogen-activated Protein (MAP) Kinase Activation and MAP Kinase-dependent Interactions between Merlin and Adherens Junction Protein Complexes in Schwann Cells

The Journal of biological chemistry, 2005-03, Vol.280 (12), p.11790-11797

2005

Volltextzugriff (PDF)

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

The lancet oncology, 2017-12, Vol.18 (12), p.1600-1609

2017

Volltextzugriff (PDF)

Regulation of Immunoproteasome Subunit Expression In Vivo Following Pathogenic Fungal Infection

The Journal of immunology (1950), 2002-09, Vol.169 (6), p.3046-3052

2002

Volltextzugriff (PDF)

Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma

Autophagy, 2014-08, Vol.10 (8), p.1380-1390

2014

Volltextzugriff (PDF)

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

Autophagy, 2014-08, Vol.10 (8), p.1369-1379

2014

Volltextzugriff (PDF)

Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma

Autophagy, 2014-08, Vol.10 (8), p.1391-1402

2014

Volltextzugriff (PDF)

Abstract CT506: Exposure-response analysis of batiraxcept and application to recommended phase 2 dose in platinum-resistant ovarian and clear cell renal cancers

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT506-CT506

2022

Volltextzugriff (PDF)

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4599-TPS4599

2022

Volltextzugriff (PDF)

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4511-4511

2022

Volltextzugriff (PDF)

Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer

Gynecologic oncology, 2021-11, Vol.163 (2), p.254-261

2021

Volltextzugriff (PDF)

Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5566-5566

2021

Volltextzugriff (PDF)

Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS5602-TPS5602

2019

Volltextzugriff (PDF)

A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS5605-TPS5605

2021

Volltextzugriff (PDF)

SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS3160-TPS3160

2019

Volltextzugriff (PDF)

Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS8105-TPS8105

2015

Volltextzugriff (PDF)

Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1 + ) advanced ovarian cancer: Updated analysis of KEYNOTE-028

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.5513-5513

2017

Volltextzugriff (PDF)

A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS5601-TPS5601

2018

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(38)
Dissertationen
(1)

Sprache

Englisch
(39)
Japanisch
(6)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC

Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial

Coordinate control of axon defasciculation and myelination by laminin-2 and -8

Erbin Regulates Mitogen-activated Protein (MAP) Kinase Activation and MAP Kinase-dependent Interactions between Merlin and Adherens Junction Protein Complexes in Schwann Cells

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

Regulation of Immunoproteasome Subunit Expression In Vivo Following Pathogenic Fungal Infection

Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma

ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-type, advanced or recurrent endometrial carcinoma (1246)

Abstract CT506: Exposure-response analysis of batiraxcept and application to recommended phase 2 dose in platinum-resistant ovarian and clear cell renal cancers

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140)

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140)

Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer

Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma

Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208)

A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004)

SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors

Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1–positive advanced non-small cell lung cancer (NSCLC)

Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1 + ) advanced ovarian cancer: Updated analysis of KEYNOTE-028

A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer

Suchergebnisse filtern